HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: co-high expression of HDAC6 and CSF1R exhibited worse progression-free survival (PFS)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The dual inhibition strategy provides a translational framework to overcome stromal and immune barriers in this recalcitrant cancer. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12943-025-02552-y.
[BACKGROUND] Small cell lung cancer (SCLC) remains a highly lethal malignancy with limited therapeutic options.
APA
Jiang Y, Yu J, et al. (2026). HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling.. Molecular cancer, 25(1), 33. https://doi.org/10.1186/s12943-025-02552-y
MLA
Jiang Y, et al.. "HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling.." Molecular cancer, vol. 25, no. 1, 2026, pp. 33.
PMID
41501879 ↗
Abstract 한글 요약
[BACKGROUND] Small cell lung cancer (SCLC) remains a highly lethal malignancy with limited therapeutic options. The purpose of this study was to investigate the central role of histone deacetylase 6 (HDAC6) in SCLC progression and its regulatory mechanisms to identify novel therapeutic strategies.
[METHODS] Preclinical SCLC models were utilized alongside molecular, cellular, and immunological techniques to elucidate HDAC6's mechanistic functions. The deacetylation of S100A2 and its impact on downstream signaling were analyzed, compensatory responses to HDAC6 inhibition were assessed, and the efficacy of dual-target inhibition was evaluated.
[RESULTS] HDAC6 was found to deacetylate the calcium-binding protein S100A2 at lysine 27, thereby stabilizing TGF-β/SMAD signaling to promote epithelial-mesenchymal transition (EMT) and metastatic dissemination. Simultaneously, HDAC6 polarized macrophages toward tumor-promoting M2 phenotypes, fostering an immunosuppressive microenvironment. HDAC6 inhibition triggered compensatory CSF1R upregulation, revealing a resistance mechanism. Dual blockade of HDAC6 and CSF1R synergistically suppressed primary tumor growth and metastasis while reprogramming macrophages toward anti-tumor M1 states. SCLC patients with co-high expression of HDAC6 and CSF1R exhibited worse progression-free survival (PFS).
[CONCLUSION] This study defines the HDAC6-S100A2-TGF-β/SMAD and HDAC6-CSF1R-macrophage axes as actionable therapeutic vulnerabilities. The dual inhibition strategy provides a translational framework to overcome stromal and immune barriers in this recalcitrant cancer.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12943-025-02552-y.
[METHODS] Preclinical SCLC models were utilized alongside molecular, cellular, and immunological techniques to elucidate HDAC6's mechanistic functions. The deacetylation of S100A2 and its impact on downstream signaling were analyzed, compensatory responses to HDAC6 inhibition were assessed, and the efficacy of dual-target inhibition was evaluated.
[RESULTS] HDAC6 was found to deacetylate the calcium-binding protein S100A2 at lysine 27, thereby stabilizing TGF-β/SMAD signaling to promote epithelial-mesenchymal transition (EMT) and metastatic dissemination. Simultaneously, HDAC6 polarized macrophages toward tumor-promoting M2 phenotypes, fostering an immunosuppressive microenvironment. HDAC6 inhibition triggered compensatory CSF1R upregulation, revealing a resistance mechanism. Dual blockade of HDAC6 and CSF1R synergistically suppressed primary tumor growth and metastasis while reprogramming macrophages toward anti-tumor M1 states. SCLC patients with co-high expression of HDAC6 and CSF1R exhibited worse progression-free survival (PFS).
[CONCLUSION] This study defines the HDAC6-S100A2-TGF-β/SMAD and HDAC6-CSF1R-macrophage axes as actionable therapeutic vulnerabilities. The dual inhibition strategy provides a translational framework to overcome stromal and immune barriers in this recalcitrant cancer.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12943-025-02552-y.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- Macrophage deficiency discordantly regulated tumor growth and metastasis through increased thrombospondin-1 production.
- Juglans mandshurica-Eleutherococcus senticosus herb pair inhibits hepatocellular carcinoma growth by inducing immunogenic cell death via the HIF-1α/STAT3 pathway.
- A Cuproptosis-related lncRNA Signature for Prognostic Stratification and Immunotherapeutic Implications in Lung Adenocarcinoma.
- Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Downregulation of ESRP2 Promotes Breast Cancer Cell Migration by Activating EMT Transcription Program Through Modulation of ENAH Variable Splicing.
- AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma.
- Lactotransferrin upregulation affects the pathological changes of non-small cell lung cancer by regulating ferroptosis.
- CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer.
- Adverse Outcome Pathway 298: Increase in Reactive Oxygen Species Leading to Human Treatment-Resistant Gastric Cancer.
- Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.